摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Epicephalotaxin | 39707-72-7

中文名称
——
中文别名
——
英文名称
Epicephalotaxin
英文别名
(2S,3R,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-ol
Epicephalotaxin化学式
CAS
39707-72-7
化学式
C18H21NO4
mdl
——
分子量
315.369
InChiKey
YMNCVRSYJBNGLD-SQNIBIBYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.2
  • 重原子数:
    23
  • 可旋转键数:
    1
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    51.2
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Epicephalotaxin吡啶氯化亚砜 作用下, 以 乙醚 为溶剂, 生成 (Ξ)-2-hydroxy-2-(3-methyl-butyl)-succinic acid 1-((3aR)-2c-methoxy-(3arC4)-2,3,5,6,8,9-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-3t-yl) ester 4-methyl ester
    参考文献:
    名称:
    重排头孢他辛酯的制备及其抗肿瘤活性。
    摘要:
    为了进一步评估头孢类生物碱之间的构效关系,制备了头孢他辛的“重排”酯(2b),它是脱氧harringtoningine(5a)的异构体。使母体生物碱头孢他辛(1a)与亚硫酰氯反应,用氯取代其羟基。用半酯6的银盐处理所得的氯化合物1b,通过烯丙基重排,随后进一步的双键迁移,得到2b。事实证明,新的“重排”脱氧harringtonine异构体2b在P-388淋巴细胞白血病系统中没有活性,因此进一步描述了该系列生物碱中抗肿瘤活性的结构要求。
    DOI:
    10.1021/jm00235a014
  • 作为产物:
    描述:
    cephalotaxinone 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 生成 Epicephalotaxin
    参考文献:
    名称:
    头杉的一些次要生物碱的结构。
    摘要:
    DOI:
    10.1021/jo00951a040
点击查看最新优质反应信息

文献信息

  • Structures of some of the minor alkaloids of Cephalotaxus fortunei
    作者:William W. Paudler、Jerry McKay
    DOI:10.1021/jo00951a040
    日期:1973.6
  • Preparation and antitumor activity of a rearranged ester of cephalotaxine
    作者:Kenneth L. Mikolajczak、Richard G. Powell、Cecil R. Smith
    DOI:10.1021/jm00235a014
    日期:1975.1
    Cephalotaxus alkaloids, a "rearranged" ester (2b) of cephalotaxine was prepared, one which is an isomer of deoxyharringtonine (5a). The parent alkaloid, cephalotaxine (1a), was allowed to react with thionyl chloride to replace its hydroxyl group with chlorine. The resulting chloro compound 1b, on treatment with the silver salt of half ester 6, yielded 2b via an allylic rearrangement followed by further double
    为了进一步评估头孢类生物碱之间的构效关系,制备了头孢他辛的“重排”酯(2b),它是脱氧harringtoningine(5a)的异构体。使母体生物碱头孢他辛(1a)与亚硫酰氯反应,用氯取代其羟基。用半酯6的银盐处理所得的氯化合物1b,通过烯丙基重排,随后进一步的双键迁移,得到2b。事实证明,新的“重排”脱氧harringtonine异构体2b在P-388淋巴细胞白血病系统中没有活性,因此进一步描述了该系列生物碱中抗肿瘤活性的结构要求。
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 nordeoxyharringtonine cephalotaxine 4′-demethylharringtonine homoharringtonine α-N-oxide cephalotaxine α-N-oxide cephalotaxine α-N-oxide cephalotaxine β-N-oxide (2R,3R,4S,5S)-2,3-bis(tert-butyldiphenylsilyloxy)-cephalotaxan-8-one (2S,3R,5S,7S)-3-methyl-4,17,19-trioxa-11-azahexacyclo[12.7.0.02,7.03,5.07,11.016,20]henicosa-1(21),14,16(20)-triene (2S,6S)-3-methyl-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),3,13,15(19)-tetraene (1S)-2-methoxy-(3atC4,14bt)-1,5,6,8,9,14b-hexahydro-4H-1r,9c-epioxido-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine 1-O-[(2R,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate 2,3,5,6,8,9-hexahydro-1-(pivaloyloxy)-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine Dimethyl 3-(trifluoromethylsulfonyloxy)-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),2,7,13,15(19)-pentaene-7,8-dicarboxylate Alkaloid D Epicephalotaxin Cephalotaxin a u. b (3aα,4aS*,15bβ,15cα)-(+/-)-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>-benzazepine 4-Hydroxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-3-one (Ξ)-2-methyl-2-(2,2,2-trichloro-ethoxycarbonyloxy)-butyric acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-2-methoxy-1t-(2,2,2-trichloro-ethoxycarbonyloxy)-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-phenyl-(2,2,2-trichloro-ethoxycarbonyloxy)-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester oxalic acid ethyl ester (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (3aR)-1t-benzyloxycarbonyloxy-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepine (S)-hydroxy-phenyl-acetic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester [(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-[2-(furan-2-ylmethylamino)-2-oxoethyl]-2,6-dihydroxy-6-methylheptanoate (+/-)-3-dehydroxy-2-demethoxy-1,2-dihydro-2,8-dioxocephalotaxine epi-deoxyharringtonine hexa-2t,4t-dienoic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester Dehydrodeoxyhomoharringtonine [(2S,4S,6S)-12-methylsulfanyl-11-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate Omacetaxine mepesuccinate hydrochloride cephalotaxinamide (1R,2S,3aS,14bR)-1,2,3,5,6,8,9,14b-Octahydro-4H-cyclopenta<1,3>dioxolo<4,5-h>pyrrolo<2,1-b><3>benzazepine-1,2-diol methylfumaric acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 11alpha-Hydroxycephalotaxine